SAB Biotherapeutics (NASDAQ: SABS), gained 28% today as the clinical-stage biopharmaceutical company pioneering a novel immunotherapy platform received approval from the Australian Human Research Ethics Committee...
Nkarta, Inc. (Nasdaq: NKTX) is making headlines with a staggering 120% surge in its share value at the present time of writing. This remarkable growth is...
Tempest Therapeutics (NASDAQ: TPST) experienced a remarkable market upswing of over 2,800%, showcasing one of the most substantial gains this year for a once tiny biotech...